Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mDOF regimen
- Development stage
- Phase 3
- Lead developer
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
mDOF is a modified neoadjuvant chemotherapy regimen consisting of docetaxel, oxaliplatin, fluorouracil (5-FU), and leucovorin. It is specifically utilized in clinical trials conducted by the Sixth Affiliated Hospital, Sun Yat-sen University, for the treatment of advanced gastric cancer. The regimen is typically administered in cycles prior to D2 radical resection and may be combined with hyperthermic intraperitoneal perfusion chemotherapy (HIPEC). Docetaxel acts as a microtubule stabilizer, oxaliplatin functions as a platinum-based DNA cross-linking agent, fluorouracil is an antimetabolite that inhibits thymidylate synthase, and leucovorin is used to potentiate the effects of fluorouracil by stabilizing its binding to the target enzyme.
- Other names
- modified DOFdocetaxel + oxaliplatin + fluorouracil + leucovorin
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on mDOF regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mDOF regimen.